Galmed Pharmaceuticals (GLMD)
NASDAQ:GLMD
Want to see GLMD full AI Analyst Report?
Top Page
Galmed Pharmaceuticals
(NASDAQ:GLMD)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.67
▼(-14.94% Downside)
Action:Reiterated
Date:04/08/26
The score is primarily constrained by weak financial performance (no revenue, recurring losses, and negative free cash flow with declining equity). Technicals also lean bearish with price below key moving averages and a negative MACD, while valuation remains difficult to support due to negative earnings and no indicated dividend yield.
Positive Factors
Low financial leverage
Very low debt reduces solvency risk and preserves flexibility to fund clinical programs via equity or partnerships. For a pre-commercial biotech, minimal leverage lowers bankruptcy risk, limits fixed financing costs, and gives management room to pursue IND-enabling work and strategic collaborations.
Negative Factors
No revenue and negative cash flow
Persistent negative operating and free cash flow without product revenue makes the company dependent on external financing to progress clinical programs. Continued cash burn constrains multi-program development, raises fundraising frequency, and increases execution risk if capital markets or partner deals are delayed.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Very low debt reduces solvency risk and preserves flexibility to fund clinical programs via equity or partnerships. For a pre-commercial biotech, minimal leverage lowers bankruptcy risk, limits fixed financing costs, and gives management room to pursue IND-enabling work and strategic collaborations.
Read all positive factors
Galmed Pharmaceuticals (GLMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.82M
Dividend YieldN/A
Average Volume (3M)84.25K
Price to Earnings (P/E)―
Beta (1Y)2.10
Revenue GrowthN/A
EPS Growth74.58%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.33
Shares Outstanding6,599,654
10 Day Avg. Volume86,643
30 Day Avg. Volume84,246
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market Cap0.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$5.72M
Galmed Pharmaceuticals Business Overview & Revenue Model
Company Description
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-al...
How the Company Makes Money
null...
Galmed Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -8.51M | -6.20M | -7.46M | -17.62M | -32.84M |
| Net Income | -10.31M | -7.52M | -6.91M | -17.87M | -32.47M |
Balance Sheet | |||||
| Total Assets | 18.63M | 18.50M | 16.63M | 16.56M | 36.60M |
| Cash, Cash Equivalents and Short-Term Investments | 18.16M | 15.33M | 12.64M | 13.79M | 34.81M |
| Total Debt | 0.00 | 0.00 | 41.00K | 215.00K | 229.00K |
| Total Liabilities | 2.85M | 2.17M | 2.75M | 3.14M | 6.11M |
| Stockholders Equity | 15.78M | 16.33M | 13.88M | 13.42M | 30.50M |
Cash Flow | |||||
| Free Cash Flow | -6.32M | -5.88M | -6.14M | -18.50M | -32.90M |
| Operating Cash Flow | -6.32M | -5.88M | -6.14M | -18.50M | -32.89M |
| Investing Cash Flow | -3.38M | -1.11M | 800.00K | 17.56M | 11.46M |
| Financing Cash Flow | 9.03M | 8.79M | 6.18M | 70.00K | 17.37M |
Galmed Pharmaceuticals Technical Analysis
Positive
0.79
Price Trends
0.63
Positive
0.65
Positive
0.93
Negative
Market Momentum
0.02
Negative
56.35
Neutral
58.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GLMD, the sentiment is Positive. The current price of 0.79 is above the 20-day moving average (MA) of 0.64, above the 50-day MA of 0.63, and below the 200-day MA of 0.93, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 56.35 is Neutral, neither overbought nor oversold. The STOCH value of 58.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GLMD.
Galmed Pharmaceuticals Risk Analysis
Galmed Pharmaceuticals disclosed 77 risk factors in its most recent earnings report. Galmed Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Galmed Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $8.61M | -0.17 | 261.84% | ― | -35.62% | 70.55% | |
45 Neutral | $8.41M | -0.52 | -334.42% | ― | ― | 79.53% | |
43 Neutral | $4.82M | -0.44 | -46.34% | ― | ― | 74.58% | |
41 Neutral | $1.84M | -0.04 | 764.53% | ― | 155.96% | 87.56% | |
41 Neutral | $3.36M | -0.09 | ― | ― | ― | 76.55% |
* Healthcare Sector Average
GLMD
Galmed Pharmaceuticals
0.70
-0.92
-57.04%
AIM
AIM ImmunoTech
0.52
-6.58
-92.74%
JAGX
Jaguar Animal Health
2.80
-130.20
-97.89%
QNRX
Quoin Pharmaceuticals
4.49
-4.03
-47.27%
SILO
Silo Pharma
5.90
-3.42
-36.70%
CLDI
Calidi Biotherapeutics
0.17
-3.77
-95.71%
Galmed Pharmaceuticals Corporate Events
Galmed and Tissue Dynamics Reveal New Metabolic Target for Cardiac Fibrosis With Aramchol Combo
Jun 2, 2026
On June 2, 2026, Galmed Pharmaceuticals and Tissue Dynamics reported preclinical data showing that a combination of Aramchol Meglumine, an SCD1 inhibitor, with a selective PPARα agonist reduced fibrotic burden about fourfold in inflammatory h...
Galmed Reports Fivefold Bioavailability Boost with New Aramchol Meglumine Oral Formulation
May 14, 2026
On May 14, 2026, Galmed Pharmaceuticals reported first-in-human pharmacokinetic data showing that a 400 mg oral formulation of Aramchol meglumine achieved approximately fivefold higher bioavailability than the currently used 300 mg Aramchol free a...
Galmed Pharmaceuticals Partners with Tissue Dynamics on Human Cardiac Fibrosis Platform
May 6, 2026
On May 6, 2026, Galmed Pharmaceuticals and Tissue Dynamics announced a collaboration to build a human-centered chronic cardiac fibrosis platform based on vascularized, sensor-embedded cardiac organoids. The model targets post‑myocardial infa...
Galmed Pharmaceuticals Teams with Tel Aviv University on Aramchol for Metastatic Brain Cancer
Apr 14, 2026
On April 14, 2026, Galmed Pharmaceuticals announced a research collaboration with Ramot at Tel Aviv University to evaluate a brain-penetrating form of its SCD1 inhibitor Aramchol as a targeted therapy for metastatic brain cancers. The project will...
Galmed Unveils Brain-Penetrant Aramchol Formulation, Expanding Flagship Drug Into CNS Diseases
Apr 9, 2026
On April 9, 2026, Galmed Pharmaceuticals announced it has co-developed with Barcode Nanotech a new lipid nanoparticle-based, subcutaneously administered formulation of its SCD1 inhibitor Aramchol that can cross the blood–brain barrier and de...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.